chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 21.0
Sex: M
Vaccine: COVID19
Symptoms: Mean cell haemoglobin concentration normal, Mean cell haemoglobin normal, Mean cell volume decreased, Mean platelet volume normal, Metabolic function test
Clinical narrative: Patient received COVID-19 Pfizer vaccine 09 Sep 2021, 1 of 2 series, and developed symptoms 15 days after this first dose. Presented with pleuritic CP day 15 Trop I 0.050 (ref 0.012) ESR 1 CRP <0.5 Eos 0.2 Treated with torrodol, ibuprofen, colchicine and discharged
Age: 21.0
Sex: M
Vaccine: COVID19
Symptoms: Monocyte count normal, Monocyte percentage increased, Neutrophil count normal, Neutrophil percentage decreased, Platelet count normal
Clinical narrative: Patient received COVID-19 Pfizer vaccine 09 Sep 2021, 1 of 2 series, and developed symptoms 15 days after this first dose. Presented with pleuritic CP day 15 Trop I 0.050 (ref 0.012) ESR 1 CRP <0.5 Eos 0.2 Treated with torrodol, ibuprofen, colchicine and discharged
Age: 21.0
Sex: M
Vaccine: COVID19
Symptoms: Pleuritic pain, Protein total normal, Prothrombin time normal, Red blood cell count normal, Red blood cell nucleated morphology
Clinical narrative: Patient received COVID-19 Pfizer vaccine 09 Sep 2021, 1 of 2 series, and developed symptoms 15 days after this first dose. Presented with pleuritic CP day 15 Trop I 0.050 (ref 0.012) ESR 1 CRP <0.5 Eos 0.2 Treated with torrodol, ibuprofen, colchicine and discharged
Age: 21.0
Sex: M
Vaccine: COVID19
Symptoms: Red blood cell sedimentation rate decreased, Troponin I increased
Clinical narrative: Patient received COVID-19 Pfizer vaccine 09 Sep 2021, 1 of 2 series, and developed symptoms 15 days after this first dose. Presented with pleuritic CP day 15 Trop I 0.050 (ref 0.012) ESR 1 CRP <0.5 Eos 0.2 Treated with torrodol, ibuprofen, colchicine and discharged
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Amnesia, Chest pain, Extra dose administered, Headache, Injection site pain
Clinical narrative: Constant shoulder pain left arm, chest pain, constant headache, memory loss, unusual pain all over my body, sleep loss, intramuscular pain.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Insomnia, Myalgia, Pain
Clinical narrative: Constant shoulder pain left arm, chest pain, constant headache, memory loss, unusual pain all over my body, sleep loss, intramuscular pain.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Alanine aminotransferase normal, Anaemia, Anion gap, Aspartate aminotransferase increased, Barbiturates negative
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Basophil percentage decreased, Benzodiazepine drug level, Bilirubin conjugated increased, Bilirubin urine, Blood albumin decreased
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Blood alkaline phosphatase normal, Blood bicarbonate decreased, Blood bilirubin increased, Blood calcium decreased, Blood chloride normal
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Blood cholesterol normal, Blood creatinine normal, Blood ethanol normal, Blood glucose normal, Blood lactate dehydrogenase increased
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Blood lactic acid, Blood magnesium normal, Blood pH normal, Blood phosphorus normal, Blood potassium normal
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Blood sodium decreased, Blood triglycerides normal, Blood urea normal, Brain natriuretic peptide increased, C-reactive protein normal
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Carbon dioxide decreased, Computerised tomogram head normal, Condition aggravated, Drug screen negative
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Eosinophil percentage, Fibrin D dimer, Glomerular filtration rate decreased, Glucose urine absent, Haematocrit decreased
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Haemoglobin decreased, High density lipoprotein decreased, Hypoglycaemia, Hypophagia, Immature granulocyte count
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Immunosuppression, International normalised ratio increased, Lipase normal, Low density lipoprotein normal, Lymphocyte percentage decreased
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Mean cell volume increased, Mental status changes, Monocyte percentage, Neutropenia, Neutrophil count normal
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Neutrophil percentage increased, Nitrite urine absent, PCO2 decreased, PO2 normal, Platelet count decreased
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Protein total decreased, Prothrombin time prolonged, Red blood cell count decreased, Red cell distribution width increased, SARS-CoV-2 test positive
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Serum ferritin increased, Specific gravity urine normal, Staphylococcus test, Tachypnoea, Thrombocytopenia
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Transaminases increased, Troponin I normal, Urine ketone body present, Urine leukocyte esterase, Urobilinogen urine
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: White blood cell count decreased, pH urine normal
Clinical narrative: 69 Y female with h/o type II DM, OSA, HTN and idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16) on Myfortic, tacrolimus, prednisone who presented to the ED secondary to AMS in the setting of hypoglycemia and decreased po intake found to have COVID 19 disease   COVID 19 disease - Symptom onset on 9/4. COVID positive on 9/10. No reported fevers." Given her lack of hypoxia and need for supplemental oxygen, she did not meet criteria for Decadron. Remdesivir was indicated given the patient's tachypnia with RR 30 on presentation.  D/w transplant physician who agreed with starting Remdesivir and recommended at least a 5 day course.  (9/10 - 9/14) for which she remained hospitalized. Mild transaminitis but improving. 9/13 Dr. advised that pt was a candidate for monoclonal antibodies (Regeneron) so this was administered after.  D/w lung transplant pulmonologist who agreed. - at discharge satting well with exertion and at rest - 20 day isolation from symptom onset - f/u with COVID transitions team   AMS  Patient presented due to AMS, likely secondary to hypoglycemia. CTH negative and mental status improved following administration of D50. Also presented to the ED 7/8 also for AMS which was also deemed to be secondary to hypoglycemia.   - Mental status now normal   Hypoglycemia / Type II DM (HbA1C 5.7 8/9/21) BG 36 upon presentation to the ED in the setting of decreased po intake and continued insulin use. Received D50 in ED with improvement. Patient was on PTA NPH 28 units in AM, Humalog 10 units for breakfast and 16 units for lunch and dinner.  Her evening NPH was stopped 8/10/21 due to AM hypoglycemia.  - Blood sugars consistently between 80 and 160 here and she only requires a few units of insulin a day - discharged and told to hold NPH and f/u with diabetic educator   Thrombocytopenia, anemia, nutripenia.   Patient with chronic thrombocytopenia, plt ~100s. Down to 71 early in her course, possibly related to COVID infection.  Myfortic dose lowered and counts slowly increasing. - CTM closely.  plt 99K at discharge and are slowly uptrending. She is to continue lowered dose of 180 mg BID rather than her usual 540 mg bid. Check labs in 2-3 days and f/u with transplant team   Idiopathic pulmonary fibrosis s/p double lung transplant (8/8/16)   - Continue PTA prednisone 7.5 mg daily, prograf and myfortic (lower dose) for immunosuppression.  - Continue CMV prophylaxis with Valcyte 450 mg BID - Continue PCP prophylaxis with Bactrim MWF - Continue Azithromycin for BOS prophylaxis.    HTN  - resume PTA Coreg
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, C-reactive protein increased, Chills, Dehydration, Delirium
Clinical narrative: Fever,  delirium, chills, severe arthralgias and myalgias, severe fatigue, inability to stand, dehydration
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Differential white blood cell count abnormal, Dysstasia, Fatigue, Haematuria, Leukopenia
Clinical narrative: Fever,  delirium, chills, severe arthralgias and myalgias, severe fatigue, inability to stand, dehydration
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Neutrophilia, Platelet count decreased, Pyrexia, Thrombocytopenia
Clinical narrative: Fever,  delirium, chills, severe arthralgias and myalgias, severe fatigue, inability to stand, dehydration
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Blood glucose decreased, Dizziness
Clinical narrative: Glucose dropped to 40 . Dizzy and light headed . Lasted about 20 mins
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Audiogram, Blood test, Dizziness, Echocardiogram, Electrocardiogram
Clinical narrative: After the vaccine, I had a sore spot on my arm and that was it. And then around the same time as I started experiencing severe dizziness with moments of vertigo (something might have been happening before my second dose in February and then it was progressing as far as kicking in, in March ) and these progressed over the next 6 months - each month the symptoms got worse and worse. I was falling. I was having severe episodes when I thought it might have been a seizure - thrown to the floor.  I went to ER in July - .. My primary care physician - Dr. He  sent me to endocrinologist and then I saw two cardiologists and then a neurologist and then an audiologist and ear, nose and throat specialist. The ENT Oto something  (specializes in ear/nerve function): My diagnosis - Bilateral Vestibular Hypo Function - Oscillopsia - I'm going back to neurologist because they they think I'm having Vestibular Migraine. No treatment. Vestibular nerves in ears that control my balance are both dead. The study might be testing for an implant and so I may try for that.  The ENT is 99.9 percent sure that I have Vestibular Migraine that I'm having.